News | June 08, 2022
Halozyme announces commercial launch of testosterone undecanoate 'TLANDO'
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
The peptide-based vaccine induces a t cell-dependent response
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
A new course at the Azrieli Faculty of Medicine will focus on tissue regeneration and 3D printing for therapeutic needs
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Routine tests undertaken by women dropped by 35% in 2020
Subscribe To Our Newsletter & Stay Updated
